Skip to main content
Press Release

Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

By June 29, 2020March 9th, 2022No Comments

EDISON, NJ / June 29, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”), today announced the advancement to the final dose level in its ongoing clinical trial of Rencofilstat, a Phase 1b multiple ascending dose (“MAD”) study.

The open-label MAD study is designed to assess safety, tolerability and pharmacokinetics of Rencofilstat, administered orally to healthy volunteers, once daily for 28 days. To date, the study has examined doses of 75 mg, 150 mg, 225 mg and 300 mg.

The Clinical Trial Management team has reviewed the 300 mg cohort data and determined this dosing level to be safe and well tolerated, authorizing advancement to the final dosing level of 375 mg daily for 28 days.

“We initially planned to proceed only to the 300 mg dosing level, as we believe the dose required to demonstrate efficacy in future NASH trials will not exceed 300 mg,” said Dr. Patrick Mayo, Hepion’s Senior Vice-President, Clinical Pharmacology. “However, we have not yet observed any dose-limiting side effects, even at 300 mg. As such, we decided to add one final dosing cohort of 375 mg to fully evaluate safety and tolerability, and pharmacokinetics of Rencofilstat. This study has demonstrated that steady-state Rencofilstat concentrations achieved at a 75 mg daily dose are in the range that demonstrates efficacy in animal models and human liver tissue. This suggests that the dosing range captured in this study effectively explored clinically relevant exposures.”

Dr. Stephen Harrison, Hepion’s Consultant Medical Director added, “We are exceedingly pleased that Rencofilstat continues to be very well tolerated throughout the entire Phase 1 program, which well positions Hepion for our upcoming Phase 2a clinical trial in NASH patients.”

About Hepion Pharmaceuticals

Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and other types of hepatitis. The Company’s lead drug candidate, Rencofilstat, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from Rencofilstat’s potent inhibition of cyclophilins, which are involved in many disease processes. Currently in clinical phase development, Rencofilstat shows potential to play an important role in the overall treatment of liver disease – from triggering events through to end-stage disease.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2019 and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580

SOURCE: Hepion Pharmaceuticals, Inc.

View source version on